Table 5 Estimates of 2011 indirect and direct costs due to haemophilia in Belgium
From: The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease
Scenario | No time discounting | 3.5% time discounting | ||
|---|---|---|---|---|
Cost | Mean total cost | Mean cost per incident case | Mean total cost | Mean cost per incident case |
|  | (95% CrI) (€) | (95% CrI) (€) | (95% CrI) (€) | (95% CrI) (€) |
Total | 97,336,761 | 7,826,097 | 32,201,550 | 2,598,176 |
(47,139,079–158,080,868) | (3,770,640–12,700,923) | (15,663,972–51,743,686) | (1,242,147–4,192,128) | |
Direct | 91,773,744 | 7,379,337 | 30,491,342 | 2,460,299 |
(44,416,357–148,640,854) | (3,534,774–11,959,182) | (14,846,997–48,928,191) | (1,173,455–3,955,981) | |
Indirect | 5,563,016 | 446,760 | 1,710,208 | 137,878 |
|  | (1,657,623–12,092,403) | (134,444–976,977) | (544,059–3,592,225) | (43,083–293,984) |